ARID1A and cutaneous melanoma: Meanwhile, there was no difference in the expression of PD-L1 by IHC in all the cutaneous melanoma cohorts (ARID1A: 43.75% vs ARID2: 51.08% vs ARID1A/2: 52.5% vs ARID-WT: 44.96%, q = 0.242)—Fig. 2a.